SCHEMBL7021175

SCHEMBL7021175

O=c1c2[nH]cnc2n(CC2CCCC2)c(=O)n1CC1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 13/20 0.56
ADORA2A P29274 12/20 0.56
PDE4A P27815 11/20 0.55
PDE4B Q07343 11/20 0.55
PDE4C Q08493 11/20 0.55
PDE4D Q08499 11/20 0.55
PDE5A O76074 1/20 0.53
PDE2A O00408 1/20 0.47
PDE1A P54750 1/20 0.47
PDE1B Q01064 1/20 0.47
PDE1C Q14123 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7025705 0.99 ADORA2B (0.55) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL9350679 0.97 PDE4A (0.54) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL7018925 0.97 ADORA2B (0.56) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL7029046 0.94 PDE4A (0.59) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL9354344 0.84 ADORA2B (0.47) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL19210142 0.82 PDE4A (0.68) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL7603838 0.79 PDE4A (0.55) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL25306092 0.78 PDE4A (0.66) ADORA2BPDE4APDE4BPDE4CPDE4D
SCHEMBL10978398 0.78 PDE4A (0.59) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL6270961 0.77 CDK2 (0.48) ADORA2BADORA2APDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0369744-B1 Xanthine derivatives, process for their preparation and pharmaceutical compositions SMITHKLINE BEECHAM PHARMA GMBH (DE) 1994-09-21 EP claimed
US-5321029-A Vascular and skin disorders; bronchodilator BEECHAM-WUELFING GMBH & CO.K.G. (DE) 1994-06-14 US claimed
EP-0369744-A2 Xanthine derivatives, process for their preparation and pharmaceutical compositions SMITHKLINE BEECHAM PHARMA GmbH (DE) 1990-05-23 EP claimed
US-6531600-B1 8-substituted xanthines have a protective effect against the consequences of cerebral metabolic inhibition; cerebral vascular and neuronal degenerative disorders; 6-aminouracil intermediate is claimed BEECHAM GROUP P.L.C. (GB) 2003-03-11 US disclosed
EP-0389282-B1 Xanthinederivatives, process for their preparation and their pharmaceutical use SMITHKLINE BEECHAM PHARMA GMBH (DE) 2002-02-20 EP disclosed
EP-1120417-A2 Xanthine derivatives for the treatment of cerebrovascular disorders SMITHKLINE BEECHAM PHARMA GmbH (DE) 2001-08-01 EP disclosed
US-6180791-B1 REDUCING NITRO GROUPS TO FORM AMINO GROUPS BEECHAM GROUP P.L.C. (GB) 2001-01-30 US disclosed
US-5981535-A FOR TREATMENT OF ALLERGIC DISORDERS ASSOCIATED WITH ATOPY, BRONCHODILATION TO TREAT DISORDERS OF THE RESPIRATORY TRACT IN A MAMMAL SMITHKLINE BEECHAM P.L.C. (GB) 1999-11-09 US disclosed
US-5734051-A TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY BEECHAM GROUP (GB) 1998-03-31 US disclosed
EP-0369744-B1 Xanthine derivatives, process for their preparation and pharmaceutical compositions SMITHKLINE BEECHAM PHARMA GMBH (DE) 1994-09-21 EP disclosed
US-5321029-A Vascular and skin disorders; bronchodilator BEECHAM-WUELFING GMBH & CO.K.G. (DE) 1994-06-14 US disclosed
EP-0389282-A2 Xanthinederivatives, process for their preparation and their pharmaceutical use BEECHAM - WUELFING GmbH & Co. KG (DE) 1990-09-26 EP disclosed
EP-0369744-A2 Xanthine derivatives, process for their preparation and pharmaceutical compositions SMITHKLINE BEECHAM PHARMA GmbH (DE) 1990-05-23 EP disclosed